Akèy › Maladi otoim › Minnesota
Etid klinik pou Maladi otoim nan Minnesota
9 etid pou Maladi otoim ap chèche patisipan nan sit nan Minnesota.
Vil nan Minnesota
Tèks ofisyèl etid la (Anglè)
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
- National Marrow Donor Program, Minneapolis
Ap rekriteFaz 2Volontè an sante akeyi
Laj 4 a 75 · Tout sèks · Mizajou Sep 28, 2026 · NCT02579967RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- Mayo Clinic - Accepting Adult Patients, Rochester
Ap rekriteFaz 2/3
Laj 6 a 75 · Tout sèks · Mizajou Sep 17, 2026 · NCT06154252Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
- Mayo Clinic: Division of Rheumatology, Rochester
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07103746RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- University of Minnesota, Minneapolis
Ap rekriteFaz 1/2
Laj 18 a 65 · Tout sèks · Mizajou Aug 26, 2026 · NCT06121297Abatacept for the Treatment of Giant Cell Arteritis
- Mayo Clinic, Rochester
Ap rekriteFaz 3
Laj 50 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT04474847RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Mayo Clinic Rochester, Rochester
Ap rekriteFaz 2/3
Laj 18 a 75 · Tout sèks · Mizajou Aug 17, 2026 · NCT06328777RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
- Mayo Clinic - Rochester, Rochester
Ap rekriteFaz 1/2
Laj 18 a 70 · Tout sèks · Mizajou Aug 13, 2026 · NCT06359041A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- University of Minnesota Medical School, Minneapolis
Ap rekriteFaz 1
Laj 12 a 70 · Tout sèks · Mizajou May 22, 2026 · NCT06308978A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
- University of Minnesota Delaware Clinical Research Unit, Minneapolis
- Mayo Clinic, Rochester
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 25, 2026 · NCT06626919Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.